A Strong Signal for Investors: VR LIFE and H2 Global Group Confirm the Value of Czech Innovations in MedTech Czech MedTech is no longer a fringe topic and is beginning to establish itself as a sector capable of combining technological innovation, clinical utility, and attractive value growth. It is precisely in this environment that H2 Global Group, a group focused on the development, clinical validation, and investment growth of healthcare technologies with international potential, is increasingly making its mark. One concrete proof that this approach works exceptionally well is the story of VR LIFE and its product, VR Vitalis.
In June 2023, H2 Investment, a subsidiary of H2 Global Group, entered VR LIFE with an investment of 15 million CZK in exchange for a 20% stake. Even then, it was an entry into a project with a strong technological foundation, clinical utility, and the ambition to scale its solutions beyond the domestic market. Today, this step demonstrates that a well-timed investment in medical technology can create significant value even before a potential strategic sale.
Another validating moment came in February 2026, when VR LIFE closed a “seed” investment round of €600,000, joined by investors such as Garage Angels and Electron CP. According to H2 Global Group materials, following this round, H2 Investment’s stake was diluted to 18.26%, but the implied value of this stake rose to approximately €1.278 million, or roughly 31.2 million CZK. This represents more than double the original investment. Although this is not a realized return, it is a clear signal that a well-chosen Czech MedTech project can be rapidly revalued at a higher valuation in its very next investment round.
The strength of this story does not rest solely on investment numbers, but primarily on the fact that VR LIFE has built a product with real-world applications in healthcare. VR Vitalis Pro is a certified medical device designed for patient rehabilitation in medical facilities. VR LIFE collaborates with institutions such as the University Hospital Ostrava, Rehabilitation Institute Hrabyně, AGEL Hospital Ostrava-Vítkovice, Darkov Spas, Beroun Rehabilitation Hospital, Malvazinky Rehabilitation Clinic, University Hospital Olomouc, Pavel Kolář Centre for Movement Medicine, or spa groups including Royal Spa and Priessnitz Medical Spa Jeseník. According to the company, the product is already deployed in over 40 healthcare facilities and private clinics.
A significant milestone was also winning the Company of the Year 2024 award in the Moravian-Silesian Region. Simultaneously, the company is developing its registration activities with the U.S. Food and Drug Administration (FDA) with the aim of entering the US market within the next few months. This exact combination of clinical utility, regulatory readiness, and foreign expansion is one of the reasons why such projects are becoming increasingly attractive to investors.
“For several years, I have dreamed of being able to help people all over the world while simultaneously building a strong and functional business model that confirms the viability of the entire system. Thanks to VR Vitalis and our unique solution, with which we are expanding abroad, this dream is gradually coming true,” says Jana Trdá, Ph.D., Founder of VR LIFE.
The fields of rehabilitation and neurorehabilitation are among the segments where digital health technologies make extraordinary sense. In a time of growing demand for care and staff shortages, solutions that increase the efficiency of care, patient motivation, and rehabilitation capacity are becoming a structural necessity. This is another reason why MedTech is increasingly interesting to investors today. Value in this segment is created not just in the product itself, but primarily in the combination of intellectual property, certification, clinical validation, regulatory readiness, and the ability to scale the solution across markets.
It is precisely within this logic that H2 Global Group’s next step must be viewed. The group is not only an investor in promising projects but is simultaneously developing its own technological and patent base through its subsidiary, H2 Medical Technologies. Part of the joint innovation framework between H2 Medical Technologies and the VR Vitalis project is also a unique, patent-pending solution that combines molecular hydrogen with virtual reality for lung rehabilitation. A utility model has already been drafted and a patent application filed for this technological combination. This step confirms that the group’s ambition is not merely to develop individual products, but to build a broader platform protected by intellectual property with the potential for further clinical validation and commercial use.
In this context, H2 Global Group as a whole comes into focus. The group is built on more than 19 years of research and development, European patent EP 3701956, and following approval by the State Institute for Drug Control (SÚKL) in January 2026, launched a clinical trial and the registration phase for the world’s first medical device utilizing molecular hydrogen through its subsidiary H2 Medical Technologies. With a current pre-money valuation of 1.6 billion CZK, the company operates with the ambition to reach a transaction value ranging from $0.5 to $1.5 billion USD, or approximately 11.5 to 34.5 billion CZK, within three years. Compared to the current valuation, this would represent a growth of approximately 600% to 2000%. For existing partners and incoming shareholders progressively entering the project, this is a very strong signal of future value development. Furthermore, the global market repeatedly confirms that strategic buyers are willing to pay very high amounts for quality healthcare technologies.
The potential of this area is further supported by more than 3,000 scientific publications focused on the use of molecular hydrogen in medicine, including over 150 human studies, which makes H2 Global Group a project with parameters that investors in medical technologies (MedTech) follow very closely. From a market perspective, it is not just another startup story, but a company that connects patent-protected technology, clinical advancement, regulatory progress, and investment growth potential.
“I have long been highly sensitive to the current state of healthcare, especially regarding children’s mental health, the quality of life of seniors, and people who are just gradually entering older age. These are some of the greatest societal challenges of our time, and it is no longer possible to ignore them. I am convinced that together with our international team, which connects top Japanese scientists and doctors with Czech experts, innovators, and other experts from abroad, we can offer the world sustainable, non-invasive, and functional solutions with a real impact on people’s quality of life. Our ambition is not just to develop new technologies, but to transform them into accessible innovations with long-term benefits for the whole of society. This approach is also embodied in our non-invasive hydrogen solution, which has future applications not only in the prevention and support of the treatment of Alzheimer’s dementia and mild cognitive impairment (MCI), but also across a wide spectrum of inflammatory processes in the body. It is exactly in these areas that medicine today is seeking new, safe, and functional ways to offer patients a higher quality of life, more effective long-term support, and, ultimately, a better and healthier society,” says David Maršálek, CEO and Founder of H2 Global Group.
The story of VR LIFE and the VR Vitalis product is therefore not just the success of a single company. For H2 Global Group, it represents concrete proof that a well-timed investment in Czech MedTech can bring not only strategic importance but also rapidly growing value. And that is exactly one of the most important signals for investors. Czech MedTech is showing today that even the domestic market can produce projects with clinical, international, and investment potential. H2 Global Group is among the companies that can not only recognize this trend but also actively co-create it.
Article Author David Maršálek – Editor-in-Chief of H2 Times News, the first hydrogen newspaper, and simultaneously the CEO and founder of H2 Global Group, which focuses on the development, clinical validation, and international scaling of healthcare technologies based on the use of molecular hydrogen, and on connecting capital with innovations in the medicine of the future.
www.H2invest.cz.
www.H2times.news.
www.MolekularniVodik.cz.
www.H2global.group